Arvee Laboratories (India) Limited has informed the Exchange regarding Board meeting held on August 12, 2025.
ARVEE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Arvee Laboratories held its board meeting on August 12, 2025 and approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell sharply to ₹748 lakhs from ₹1,060 lakhs in the same quarter last year, a drop of about 29%. Profit after tax also declined steeply to ₹16.91 lakhs from ₹94.21 lakhs YoY, while EPS dropped to ₹0.15 from ₹0.85. On a sequential basis (vs Q4 FY25), revenue rose roughly 16% and PAT more than doubled from ₹6.92 lakhs. The board also appointed Mr. Saurin Ajitbhai Gandhi, the company's current CFO, as an Additional Director, and fixed September 24, 2025 as the date for the AGM, with book closure from September 20–24, 2025. The statutory auditor issued an unmodified limited review report.
Weak YoY performance — both top line and bottom line shrank significantly compared to Q1 FY25, which could weigh on short-term sentiment. However, sequential improvement and stable auditor commentary provide some comfort for shareholders.